General Information of Drug (ID: DM3R7BT)

Drug Name
US9127005, P2B Drug Info
Synonyms SCHEMBL12965084; CHEMBL3910701; BDBM179743; US9127005, P2B
Cross-matching ID
PubChem CID
50902792
TTD Drug ID
DM3R7BT

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Investigative Drug(s)
Drug(s) Targeting Phospholipase D1 (PLD1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
US9127005, P2C DMMT98V N. A. N. A. Patented [1]
US9453017, 1 DMVQ3IX N. A. N. A. Patented [2]
ML272 DMNEY58 N. A. N. A. Patented [2]
US9127005, P0L DMKLYCV N. A. N. A. Patented [1]
US9453017, 2 DMPH05Y N. A. N. A. Patented [2]
1-(pyridin-2-yl)piperazine DMKE7FG Discovery agent N.A. Investigative [3]
HALOPEMIDE DMF6V8W Discovery agent N.A. Investigative [4]
1-(pyridin-4-yl)piperazine DM78AJ1 Discovery agent N.A. Investigative [3]
⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phospholipase D1 (PLD1) TT3T17P PLD1_HUMAN Inhibitor [1]

References

1 Isoform selective phospholipase D inhibitors. US9127005.
2 Antiviral therapies with phospholipase D inhibitors. US9453017.
3 Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privil... Bioorg Med Chem Lett. 2009 Apr 15;19(8):2240-3.
4 Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol. 2009 Feb;5(2):108-17.